|
|
|
| Effects of Wisconsin and Siruikang on Weight Gain Endocrine and Metabolism in Hospitalized Male Patients with Schizophrenia |
| XIONG Qian, YU Jianying, YAN Kai, et al |
| Mental Health Center, West China Hospital, Sichuan University, Sichuan Chengdu 610041, China |
|
|
|
|
Abstract Objective: To analyze the effects of wisconsin and Siruikang treatment on weight gain, endocrine and metabolism in hospitalized male patients with schizophrenia. Methods: A total of 126 male schizophrenia patients who were treated in the hospital from Aug. 2016 to Aug. 2018 were enrolled in the study. They were randomly divided into wisconsin group and the Siruikang group, 63 cases in each group. The curative effect, changes in body mass, fasting plasma glucose (FPG), blood lipids [total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) ], endocrine hormones [prolactin (PRL), testosterone, free triiodothyronine (FT3), free thyroxine (FT4) ] before and after treatment were compared between the two groups. The occurrence of adverse reactions during treatment in both groups was statistically analyzed. Results: There was no significant difference in the effective rate of treatment between the wisconsin group and the Siruikang group (87.30% vs 88.89%, P>0.05). There was no significant difference in BMI, FPG, TC, TG, HDL, LDL, testosterone, FT3 or FT4 level in Siruikang group before and after treatment (P>0.05). There was no significant difference in FPG, HDL, LDL, PRL, testosterone, FT3 or FT4 level in wisconsin group before and after treatment (P>0.05). After treatment, level of PRL in Siruikang group was higher than that before treatment and that in wisconsin group (P<0.05). After treatment, levels of BMI, TC and TG in wisconsin group were higher than those before treatment and those in Siruikang group (P<0.05). The incidence of adverse reactions in siruikang group was significantly higher than that in wisconsin group (61.90% vs 33.33%, P<0.05). Conclusion: The curative effect of wisconsin and Siruikang is comparable on male schizophrenia patients. However, the effects of Siruikang are less on vertebral reaction and endocrine, with lower effects on sexual function, which increases treatment compliance of male patients.
|
|
|
|
|
|
[1] Macdonald S,Halliday J,MacEWAN T,et al.Nithsdale Schizophrenia Surveys 24:sexual dysfunction.Case-control study.[J].Br Psychiatry,2018,182(1):50~56.
[2] Keefe R S,Kahn R S.Cognitive decline and disrupted cognitive trajectory in schizophrenia[J].Jama Psychiatry,2017,74(5):535~536.
[3] 周进涛,崔中芹,刘燕朋,等.二甲双胍缓释片治疗非典型抗精神病药致精神分裂症糖脂代谢紊乱的临床研究[J].川北医学院学报,2016,31(1):55~57.
[4] 刘连忠,张娟,吕路,等.利培酮、喹硫平、齐拉西酮对首发女性精神分裂症患者妊娠的影响[J].基因组学与应用生物学,2017,36(4):1403~1409.
[5] 陈强,周芳珍,农玉贤.奎硫平联合齐拉西酮或氯氮平治疗难治性精神分裂症的临床观察[J].临床精神医学杂志,2016,26(1):53.
[6] 安培玉,孙杰峰,段惠峰,等.奥氮平与氟哌啶醇改善老年精神分裂症精神症状及认知功能的差异性研究[J].华南国防医学杂志,2017,31(11):723~725.
[7] 侯云跃,范林钰,刘茂航.利培酮、喹硫平单用和分别联合盐酸舍曲林治疗精神分裂症的临床对比研究[J].广西医科大学学报,2016,33(6):985~988.
[8] Rojo L E,Gaspar P A,Silva H,et al.Metabolic syndrome and obesity among users of second generation antipsychotics:a global challenge for modern psychopharmacology[J].Pharmacological Research,2015,101(26):74~85.
[9] 陈勤,杨栋,邓丽俐,等.抗精神病药物对精神分裂症患者血清泌乳素影响的研究[J].精神医学杂志,2017,30(5):340~342. |
|
|
|
2020, Vol. 26 
